secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001437749-23-021281
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx reclassifies DSUVIA as discontinued in FY2022 10-K after March 2023 asset sale to Alora
--------------------------------------------------------------------------------

- On March 12, 2023, AcelRx sold DSUVIA/DZUVEO assets to Vertical Pharmaceuticals (Alora) and classified the business as discontinued from Q1 2023.
- 2022 Form 10-K MD&A and financial statements restated to show DSUVIA as discontinued operations for all periods presented.
- Continuing operations exclude DSUVIA; remaining business includes Zalviso, other pipeline, and collaboration revenue.
- Restatement aligns with discontinued operations presentation in Q1 2023 10-Q; no other changes to 2022 10-K.
- Cash, equivalents, and investments totaled $17.7M at December 31, 2022 (per restated balance sheet).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923021281/0001437749-23-021281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923021281/acrx20230717_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer